PLSE

PLSE

USD

Pulse Biosciences Inc Common Stock (DE)

$16.060-0.440 (-2.667%)

リアルタイム価格

Healthcare
Medical Instruments & Supplies
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$16.500

高値

$16.770

安値

$15.800

出来高

0.11M

企業ファンダメンタルズ

時価総額

1.1B

業種

Medical Instruments & Supplies

United States

取引統計

平均出来高

0.18M

取引所

NCM

通貨

USD

52週レンジ

安値 $13.766現在値 $16.060高値 $25

関連ニュース

BusinessWire

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

First U.S. Surgical Treatments with PFA Clamp for Patients with Atrial Fibrillation During Concomitant Surgical Procedure Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology

もっと見る
Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study
BusinessWire

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025

Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it

もっと見る
Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025
BusinessWire

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Successfully treated atrial fibrillation (AF) in initial 30 patients with the nPulse™ Cardiac Surgical System Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology

もっと見る
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
BusinessWire

Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced

もっと見る
Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting